These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
402 related articles for article (PubMed ID: 10974184)
21. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. Alexander JH; Harrington RA Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986 [TBL] [Abstract][Full Text] [Related]
22. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes. Li Y; Spencer FA; Ball S; Becker RC J Thromb Thrombolysis; 2000 Aug; 10(1):69-76. PubMed ID: 10947916 [TBL] [Abstract][Full Text] [Related]
23. Comparison of heparin, bivalirudin, and different glycoprotein IIb/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: A network meta-analysis. Lipinski MJ; Lee RC; Gaglia MA; Torguson R; Garcia-Garcia HM; Pichard AD; Satler LF; Waksman R Cardiovasc Revasc Med; 2016 Dec; 17(8):535-545. PubMed ID: 27842901 [TBL] [Abstract][Full Text] [Related]
24. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease. Berkowitz SD Haemostasis; 2000; 30 Suppl 3():27-43. PubMed ID: 11182626 [TBL] [Abstract][Full Text] [Related]
26. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Adgey AA Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518 [TBL] [Abstract][Full Text] [Related]
27. Emergency coronary artery bypass surgery in the era of glycoprotein IIb/IIIa receptor antagonist use. Pang JT; Fort S; Della Siega A; Cohen EA J Card Surg; 2002; 17(5):425-31. PubMed ID: 12630543 [TBL] [Abstract][Full Text] [Related]
28. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Tcheng JE Am J Cardiol; 1996 Aug; 78(3A):35-40. PubMed ID: 8751845 [TBL] [Abstract][Full Text] [Related]
29. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. EPILOG Investigators N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212 [TBL] [Abstract][Full Text] [Related]
30. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials. Tricoci P; Newby LK; Hasselblad V; Kong DF; Giugliano RP; White HD; Théroux P; Stone GW; Moliterno DJ; Van de Werf F; Armstrong PW; Prabhakaran D; Rasoul S; Bolognese L; Durand E; Braunwald E; Califf RM; Harrington RA Circ Cardiovasc Qual Outcomes; 2011 Jul; 4(4):448-58. PubMed ID: 21712522 [TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of low-dose unfractionated heparin during percutaneous coronary revascularisation and the relationship between activated clotting time and haemorrhagic or ischaemic complications: our results. Capuano C; Sesana M; Leonzi O; Cuccia C J Cardiovasc Med (Hagerstown); 2006 Dec; 7(12):866-71. PubMed ID: 17122672 [TBL] [Abstract][Full Text] [Related]
40. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Roffi M; Mukherjee D; Chew DP; Bhatt DL; Cho L; Robbins MA; Ziada KM; Brennan DM; Ellis SG; Topol EJ Circulation; 2002 Dec; 106(24):3063-7. PubMed ID: 12473552 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]